A
ARQT icon

AlphaQuest’s Arcutis Biotherapeutics ARQT Stock Holding History

AlphaQuest’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,175
Closed -$295K – 159
2025
Q4 		$295K Sell
10,175
-2,428
-19% -$62.2K 0.02% 1220
2025
Q3 		$238K Buy
12,603
+682
+6% +$10.8K 0.02% 1310
2025
Q2 		$167K Buy
11,921
+5,994
+101% +$84K 0.02% 1229
2025
Q1 		$92.7K Sell
5,927
-1,215
-17% -$17.1K 0.01% 1327
2024
Q4 		$99.5K Sell
7,142
-35,696
-83% -$391K 0.01% 1094
2024
Q3 		$398K Buy
+42,838
New +$423K 0.04% 759
2024
Q2 		– Sell
-6,452
Closed -$63.9K – 1577
2024
Q1 		$63.9K Buy
+6,452
New +$48.2K 0.01% 897

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AlphaQuest's ARQT Position: Q1 2026 in Review

AlphaQuest sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 10,175 shares — an estimated $295K sold.

AlphaQuest first reported a position in ARQT in Q1 2024 and held it in 7 quarters. The position peaked at $398K in Q3 2024. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • AlphaQuest reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 10,175 Arcutis Biotherapeutics shares in Q1 2026, an estimated $295K.
  • AlphaQuest first reported a position in Arcutis Biotherapeutics in Q1 2024 and held it in 7 quarters.
  • AlphaQuest's Arcutis Biotherapeutics position peaked at $398K in Q3 2024.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.